HCW Biologics Raises Up to $10M in Secured Debt From Streeterville Capital
HCWB is trading near its 52-week low of $1.08 (0.9% above the low).
Summary
HCW Biologics closed a $10.0 million secured debt financing with Streeterville Capital — $3.0 million in cash now and $7.0 million held in a lender-controlled account released as the first note is repaid. The money is earmarked to finish the HCW9302 Phase 1 study, but the terms are expensive and the company remains cash-constrained.
Key Events · Financing and Capital Events · HCWB
-
Up to $10M Secured Debt Closed
On November 3, 2026, HCW Biologics signed a Notes Purchase Agreement with Streeterville Capital covering a $3.24 million A-1 Note and a $7.0 million B Note; the deal closed November 4, 2026.
-
Only $3.0M Cash at Closing
Net cash to the company was $2.97 million — the lender paid $3.0 million less $30,000 of transaction costs. The $7.0 million B Note sits in an HCWB Holdings deposit account under a control agreement and is released only as the B Note is exchanged for A Notes.
-
Expensive Terms and Penalties
The A-1 Note carries 8% interest and a $240,000 original issue discount. If it is still outstanding after 90 days, a monitoring fee equal to the balance divided by 0.85 minus the balance is added; trigger events can raise the balance by 10% (major) or 5% (minor), with 15% default interest.
-
Subsidiary Pledged as Collateral
Collateral includes 100% of the membership interests in newly formed HCWB Holdings, LLC, which also guarantees the notes; covenants bar new variable-rate debt and other liens without lender consent.
Analysis · HCWB · Life Sciences
Survival is the first order of business here: HCW Biologics had $741,324 in cash and a going-concern warning as of its last 10-Q. The deal delivers $3.0 million now, with a further $7.0 million available only as the first note is paid down — the second note sits in a locked account the lender controls. And the cost is steep: 8% interest on the A-1 Note, a $240,000 original issue discount, a monitoring fee that adds roughly 17.6% to the balance if the note is still outstanding after 90 days, and 10%/5% balance penalties on trigger events. Collateral covers 100% of the membership interests in the new HCWB Holdings subsidiary, and covenants bar other variable-rate debt without lender consent. Management says the money funds completion of the HCW9302 Phase 1 alopecia areata study and the Recommended Phase 2 Dose, expected in the first quarter of 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCWB was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.08 to $23.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.